Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Microarray for activated B cells compared to naive B cells

ABSTRACT: B cells encounter antigen to activate and then differentiate into plasma cells. Both multiple myeloma (MM) and some autoimmune diseases such as multiple sclerosis (MS) and systemic lupus erythematosus (SLE) are characterized with abnormal production of plasma cells. In both diseases, the process of B cells differentiate into plasma cell is disordered. To explore the novel therapeutic target to the process from naïve B cells to plasma cells via activated B cells, we determined the gene expression profile in activated B cells by affymetrix microarrays. Splenic activated CD5+B cells were sorted from 7-9-week female C57BL/6 mice by FACS and from EAE (MOG-induced chronic experimental allergic encephalomyelitis (EAE) in C57BL/6 mice is an animal model for MS) by CD19 microbeads, respectively. The transcripts in B cells were determined by Affymetrix Microarrays.

INSTRUMENT(S): Agilent 2100 Bioanalyzer, Microbeads, Affymetrix mouse gene 1.0 ST arrays, GeneChip Instrument System

ORGANISM(S): Mus musculus

SUBMITTER: Renxi Wang

PROVIDER: E-MTAB-7110 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Similar Datasets

Project description:Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disease of the central nervous system (CNS). Ursolic acid (UA) can be used in the MS treatment with anti-inflammatory and neuroprotective activities. However, UA is insoluble in water, which may affect its medication effectiveness. In this study, we evaluated the pharmacological effects of UAOS-Na, a water-soluble UA derivative, on experimental autoimmune encephalomyelitis (EAE) mouse, explored its underlying mechanism, and verified the mechanism by in vitro and in vivo experiments. As we expected, UAOS-Na (30 mg/kg/d) delayed the onset time of EAE from 11.78 days post immunization (dpi) to 14.33 dpi, reduced the incidence from 90.0% to 42.9%, and was more effective than UA. UAOS-Na (60 mg/kg/d) significantly decreased the serum levels of IFN-γ, IL-17A, TNF-α and IL-6, reduced the mononuclear cell infiltration of spinal cord, and inhibited the overexpression of key transcription factors T-bet and ROR-γt of EAE mouse spinal cord and spleen. In addition, UAOS-Na attenuated demyelination and astrogliosis in the CNS of EAE and Cuprizone-induced mice. Mechanically, proteomics showed that 217 differential expression proteins (DEPs) were enriched and 215 were upregulated in EAE mice. After UAOS-Na treatment, 52 DEPs were enriched and 49 were downregulated, and these DEPs were markedly enriched in inositol phosphate metabolism, calcium, sphingolipid, cAMP, and antigen processing and presentation (APP) signaling pathways. Among them, there were few studies on APP signaling pathway related with MS. Therefore, we further investigated the effect of UAOS-Na on APP signaling pathway and found that UAOS-Na downregulated the protein levels of Tapbp and H2-T23 in MHC-I antigen presentation pathway and decreased the proliferation of splenic CD8 T cells, thereby inhibiting the CNS infiltration of CD8 T cells. Together, our findings demonstrated that UAOS-Na have both direct anti-demyelination and anti-inflammation effects. And it could reduce the inflammation of MS by downregulating the expression of Tapbp and H2-T23 in the MHC-I antigen presentation pathway.

Dataset Information

Microarray for activated B cells compared to naive B cells

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure